Abbott Laboratories (NYSE:ABT) Price Target Lowered to $140.00 at BTIG Research

Abbott Laboratories (NYSE:ABT) had its price target reduced by BTIG Research from $145.00 to $140.00 in a research note issued to investors on Friday,Benzinga reports. BTIG Research currently has a buy rating on the healthcare product maker’s stock.

ABT has been the subject of several other reports. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating for the company in a research note on Friday, January 9th. Benchmark started coverage on shares of Abbott Laboratories in a research report on Friday, October 10th. They set a “buy” rating and a $145.00 price target for the company. Mizuho upped their price objective on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, October 14th. Royal Bank Of Canada reissued an “outperform” rating and set a $147.00 target price on shares of Abbott Laboratories in a report on Thursday, October 16th. Finally, Barclays upped their price target on shares of Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $140.79.

Abbott Laboratories Trading Down 1.1%

Shares of Abbott Laboratories stock opened at $107.46 on Friday. The firm’s 50 day simple moving average is $124.77 and its two-hundred day simple moving average is $128.36. The firm has a market capitalization of $186.86 billion, a price-to-earnings ratio of 28.89, a PEG ratio of 1.80 and a beta of 0.72. Abbott Laboratories has a 12-month low of $105.78 and a 12-month high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Brighton Jones LLC raised its holdings in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its position in shares of Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares in the last quarter. Signet Financial Management LLC lifted its position in shares of Abbott Laboratories by 6.5% during the 2nd quarter. Signet Financial Management LLC now owns 3,066 shares of the healthcare product maker’s stock valued at $417,000 after buying an additional 188 shares in the last quarter. McAdam LLC grew its stake in Abbott Laboratories by 15.7% in the 2nd quarter. McAdam LLC now owns 2,780 shares of the healthcare product maker’s stock valued at $378,000 after acquiring an additional 377 shares during the period. Finally, Register Financial Advisors LLC increased its holdings in Abbott Laboratories by 49.5% in the 2nd quarter. Register Financial Advisors LLC now owns 3,590 shares of the healthcare product maker’s stock worth $488,000 after acquiring an additional 1,188 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: MedTech and pharma strength, and EPS resilience — Abbott reported adjusted Q4 EPS growth (company highlighted margin improvements) and strong MedTech (+~12%) and Established Pharma (+~9%) performance that partly offset Nutrition weakness; management still projects FY‑2026 adjusted EPS growth. Press Release
• Positive Sentiment: Analysts keep buy/outperform stance despite cuts — several major firms trimmed price targets after the print but largely maintained buy/overweight ratings, signaling conviction in the longer‑term story even as near‑term expectations were tempered. Analyst Reaction
• Positive Sentiment: Some commentators view the pullback as a buying opportunity — market commentators highlight ABT’s dividend history, cash flow and buyback capacity, suggesting the drop may create an attractive entry for long‑term investors. MarketBeat: Pullback Analysis
• Neutral Sentiment: Full earnings call and transcripts available — investors can review management commentary and segment detail in the Q4 earnings call transcript for color on nutrition, diagnostics and Exact/other strategic items. Earnings Transcript
• Neutral Sentiment: Dividend/valuation commentary circulates — value and dividend‑focused outlets are flagging ABT as attractively valued after the pullback; this is background context rather than a near‑term catalyst. Zacks: Value Take
• Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics — Q4 revenue (~$11.5B) fell short of consensus, with Nutrition down sharply (~8–9%) and Diagnostics weak, sparking the initial selloff. Reuters: Revenue Miss
• Negative Sentiment: Guidance slightly below Street — Abbott set Q1 EPS and FY‑2026 EPS ranges that sit near or a touch below consensus, increasing near‑term revenue/growth concerns. Guidance Details
• Negative Sentiment: Multiple price‑target cuts — a raft of firms (Citigroup, Goldman, Raymond James, Sanford Bernstein, Oppenheimer, RBC, etc.) trimmed targets, which can amplify selling pressure even if ratings remain constructive. Benzinga: PT Cuts
• Negative Sentiment: Options and hedging activity spiked — an unusual surge in put buying suggests traders are positioning for further near‑term downside (heightened bearish sentiment).
• Negative Sentiment: Regulatory scrutiny in India — reports of an investigation into alleged misuse of a codeine‑based cough syrup (Abbott Healthcare) add an extra headline risk in emerging markets. Reuters: India Scrutiny

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.